Stonebridge Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-320
| Closed | -$247K | – | 81 |
|
|
2026
Q1 | $247K | Buy |
+320
| New | +$245K | 0.11% | 73 |
|
|
2025
Q2 | $255K | Hold |
485
| – | – | 0.1% | 79 |
|
|
2025
Q1 | $308K | Sell |
485
-250
| -34% | -$172K | 0.13% | 69 |
|
|
2024
Q4 | $524K | Hold |
735
| – | – | 0.21% | 60 |
|
|
2024
Q3 | $773K | Hold |
735
| – | – | 0.31% | 48 |
|
|
2024
Q2 | $773K | Hold |
735
| – | – | 0.33% | 48 |
|
|
2024
Q1 | $707K | Hold |
735
| – | – | 0.32% | 49 |
|
|
2023
Q4 | $646K | Hold |
735
| – | – | 0.32% | 49 |
|
|
2023
Q3 | $605K | Sell |
735
-10
| -1% | -$7.86K | 0.33% | 48 |
|
|
2023
Q2 | $535K | Hold |
745
| – | – | 0.25% | 58 |
|
|
2023
Q1 | $612K | Hold |
745
| – | – | 0.29% | 55 |
|
|
2022
Q4 | $538K | Sell |
745
-175
| -19% | -$129K | 0.26% | 57 |
|
|
2022
Q3 | $634K | Hold |
920
| – | – | 0.33% | 49 |
|
|
2022
Q2 | $544K | Hold |
920
| – | – | 0.25% | 60 |
|
|
2022
Q1 | $643K | Hold |
920
| – | – | 0.23% | 60 |
|
|
2021
Q4 | $581K | Hold |
920
| – | – | 0.2% | 63 |
|
|
2021
Q3 | $556K | Hold |
920
| – | – | 0.2% | 63 |
|
|
2021
Q2 | $514K | Hold |
920
| – | – | 0.19% | 67 |
|
|
2021
Q1 | $435K | Hold |
920
| – | – | 0.17% | 69 |
|
|
2020
Q4 | $445K | Hold |
920
| – | – | 0.18% | 67 |
|
|
2020
Q3 | $515K | Hold |
920
| – | – | 0.24% | 59 |
|
|
2020
Q2 | $560K | Sell |
920
-50
| -5% | -$28.4K | 0.29% | 52 |
|
|
2020
Q1 | $474K | Sell |
970
-50
| -5% | -$20.6K | 0.27% | 60 |
|
|
2019
Q4 | $383K | Sell |
1,020
-75
| -7% | -$25.2K | 0.17% | 79 |
|
|
2019
Q3 | $304K | Sell |
1,095
-324
| -23% | -$95.9K | 0.14% | 85 |
|
|
2019
Q2 | $445K | Sell |
1,419
-740
| -34% | -$246K | 0.18% | 80 |
|
|
2019
Q1 | $887K | Sell |
2,159
-60
| -3% | -$24.7K | 0.32% | 60 |
|
|
2018
Q4 | $829K | Sell |
2,219
-25
| -1% | -$9.15K | 0.33% | 63 |
|
|
2018
Q3 | $907K | Sell |
2,244
-255
| -10% | -$97K | 0.31% | 63 |
|
|
2018
Q2 | $902K | Buy |
2,499
+166
| +7% | +$51.9K | 0.32% | 62 |
|
|
2018
Q1 | $750K | Buy |
2,333
+605
| +35% | +$210K | 0.27% | 67 |
|
|
2017
Q4 | $634K | Buy |
+1,728
| New | +$700K | 0.23% | 71 |
|
Other funds holding REGN
Stonebridge Capital Management's REGN Position: Q2 2026 in Review
Stonebridge Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 320 shares — an estimated $247K sold.
Stonebridge Capital Management first reported a position in REGN in Q4 2017 and held it in 32 quarters. The position peaked at $907K in Q3 2018. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Stonebridge Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Stonebridge Capital Management sold 320 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $247K.
- Stonebridge Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 32 quarters.
- Stonebridge Capital Management's Regeneron Pharmaceuticals position peaked at $907K in Q3 2018.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Stonebridge Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.